Hiving off the fonda component makes sense.
It's probably not too hard to work out probability and reasonable capital value of future payments.
Apart from oral fonda (which sounds less likely these days), there are no downstream developments planned. Presumably they could still work on oral if they wished to.
Fonda also doesn't sit comfortably with the HyAct or VAST opportunities.
ACL's strength is in development. Selling fonda would remove any $$$ constraints on pushing the HyAct options through the pipeline ASAP.
takeover target yes - will it be sold? no way, page-6
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $1.409M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
| TSN (ASX) Chart |
Day chart unavailable